REGENXBIO Presents Positive Interim Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced additional positive interim data from the ongoing Phase II ALTITUDE™ trial of RGX-314 for the...

Related Keywords

United States ,Dana Cormack ,Michaela Klufas ,Chris Brinzey ,Steve Pakola ,Technology Platform ,Technology Platform Licensees ,Thomas Jefferson University ,Nasdaq ,Clearside Biomedical Inc ,Retina Service ,Exchange Commission ,Corporate Communications ,Securities Exchange ,Wills Eye Hospital ,Assistant Professor ,Thomas Jefferson ,Chief Medical Officer ,Safety Update ,Six Months ,Clearside Biomedical ,Platform Licensees ,Securities Act ,Securities Exchange Act ,Financial Condition ,Regenxbio Inc ,